Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tirzepatide in Idiopathic Intracranial Hypertension (TIIHT)
NCT07191873Phase 4Recruiting
- Sponsor
- Duke University
- Start
- Aug 2026
- Primary completion
- Aug 2027
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in idiopathic intracranial hypertension (IIH) comparing Tirzepatide with Placebo (2 arms). Primary endpoint: Change in Intracranial Pressure at 12 months. Started Aug 2026; status: recruiting.
02
Drugs
03
Conditions
idiopathic intracranial hypertension (IIH)
Beyond the preview
Go deeper on NCT07191873.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07191873.